Movatterモバイル変換


[0]ホーム

URL:


US20030119104A1 - Chromosome-based platforms - Google Patents

Chromosome-based platforms
Download PDF

Info

Publication number
US20030119104A1
US20030119104A1US10/161,403US16140302AUS2003119104A1US 20030119104 A1US20030119104 A1US 20030119104A1US 16140302 AUS16140302 AUS 16140302AUS 2003119104 A1US2003119104 A1US 2003119104A1
Authority
US
United States
Prior art keywords
cell
aces
chromosome
dna
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/161,403
Inventor
Edward Perkins
Carl Perez
Michael Lindenbaum
Amy Greene
Josephine Leung
Elena Fleming
Sandra Stewart
Joan Shellard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority to US10/161,403priorityCriticalpatent/US20030119104A1/en
Assigned to CHROMOS MOLECULAR SYSTEMS, INC.reassignmentCHROMOS MOLECULAR SYSTEMS, INC.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: FLEMING, ELENA, GREENE, AMY, LEUNG, JOSEPHINE, LINDENBAUM, MICHAEL, PEREZ, CARL, PERKINS, EDWARD, SHELLARD, JOAN, STEWART, SANDRA
Publication of US20030119104A1publicationCriticalpatent/US20030119104A1/en
Priority to US11/006,076prioritypatent/US7521240B2/en
Priority to US11/082,154prioritypatent/US20060024820A1/en
Priority to US11/480,175prioritypatent/US20060246586A1/en
Assigned to PENDER NDI LIFE SCIENCES FUND (VCC) INC.reassignmentPENDER NDI LIFE SCIENCES FUND (VCC) INC.SECURITY AGREEMENTAssignors: CELEXSYS, INC., CHROMOS CORPORATION, CHROMOS MOLECULAR SYSTEMS, INC.
Assigned to GLAXO GROUP LIMITEDreassignmentGLAXO GROUP LIMITEDASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: CHROMOS MOLECULAR SYSTEMS, INC.
Priority to US12/985,478prioritypatent/US20120064578A1/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

Artificial chromosomes, including ACes, that have been engineered to contain available sites for site-specific, recombination-directed integration of DNA of interest are provided. These artificial chromosomes permit tractable, efficient, rational engineering of the chromosome for a variety of applications.

Description

Claims (123)

What is claimed is:
1. A eukaryotic chromosome comprising one or a plurality of att site(s), wherein:
an att site is heterologous to the chromosome; and
an att site permits site-directed integration in the presence of lambda integrase.
2. The eukaryotic chromosome ofclaim 1, wherein the att sites are selected from the group consisting of attP and attB or attL and attR, or variants thereof.
3. The eukaryotic chromosome ofclaim 1 that is an artificial chromosome.
4. The eukaryotic chromosome ofclaim 1 that is an artificial chromosome expression system (ACes).
5. The eukaryotic chromosome ofclaim 4 that is predominantly heterochromatin.
6. The chromosome ofclaim 1 that is an artificial chromosome that contains no more than about 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% euchromatin.
7. The chromosome ofclaim 1 that is a plant chromosome.
8. The chromosome ofclaim 1 that is an animal chromosome.
9. The chromosome ofclaim 7 that is a plant artificial chromosome.
10. The chromosome ofclaim 8 that is an animal artificial chromosome.
11. The chromosome ofclaim 8 that is a mammalian chromosome.
12. The chromosome ofclaim 11 that is a mammalian artificial chromosome.
13. The chromosome ofclaim 6 that is an artificial chromosome expression system (ACes).
14. A platform artificial chromosome expression system (ACes) comprising one or a plurality of sites that participate in recombinase catalyzed recombination.
15. The ACes ofclaim 14 that contains one site.
16. The ACes ofclaim 14 that is predominantly heterochromatin.
17. The ACes ofclaim 14 that contains no more than about 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% euchromatin.
18. The ACes ofclaim 14 that is a plant ACes.
19. The ACes ofclaim 14 that is an animal ACes.
20. The ACes ofclaim 14 that is selected from a fish, insect, reptile, amphibian, arachnid or a mammalian ACes.
21. The ACes ofclaim 14 that is a fish ACes.
22. The artificial chromosome expression system (ACes) ofclaim 14, wherein the recombinase and site(s) are from the Cre/lox system of bacteriophage P1, the int/att system of lambda phage, the FLP/FRT system of yeast, the Gin/gix recombinase system of phage Mu, the Cin recombinase system, the Pin recombinase system ofE. coliand the R/RS system of the pSR1 plasmid, or any combination thereof.
23. A method of introducing heterologous nucleic acid into a chromosome, comprising:
contacting a chromosome ofclaim 1 with a nucleic acid molecule comprising both the heterologous nucleic acid and a recombination site, in the presence of a recombinase that promotes recombination between the sites in the chromosome and in the nucleic acid molecule.
24. The method ofclaim 23, wherein the recombinase is selected from the group consisting of Cre, Gin, Cin, Pin, FLP, a phage integrase and R from the pSR1 plasmid.
25. The method ofclaim 23, wherein the nucleic acid molecule encodes a therapeutic protein, antisense nucleic acid, or comprises an artificial chromosome.
26. The method ofclaim 25, wherein the nucleic acid molecule comprises a yeast artificial chromosomes (YAC), a bacterial artificial chromosome (BAC) or an insect artificial chromosome (IAC).
27. A combination, comprising, the chromosome ofclaim 1 and a first vector comprising the cognate recombination site, wherein the cognate recombination site is a site that recombines with the site engineered into the chromosome.
28. The combination ofclaim 27, further comprising nucleic acid encoding a recombinase, wherein the nucleic acid is on a second vector or on the first vector, or on the ACes under an inducible promoter.
29. The combination ofclaim 28, wherein the recombinase and sites are from the Cre/lox system of bacteriophage P1, the int/att system of lambda phage, the FLP/FRT system of yeast, the Gin/gix recombinase system of phage Mu, the Pin recombinase system ofE. coliand the R/RS system of the pSR1 plasmid, or any combination thereof.
30. The combination ofclaim 28, wherein a vector is the plasmid pCXLamIntR.
31. The combination ofclaim 27, wherein a vector is the plasmid pDsRedN1-attB.
32. A kit, comprising the combination ofclaim 27 and optionally instructions for introducing heterologous nucleic acid into the chromosome.
33. A method for introducing heterologous nucleic acid into a platform artificial chromosome, comprising:
(a) mixing an artificial chromosome comprising at least a first recombination site and a vector comprising at least a second recombination site and the heterologous nucleic acid;
(b) incubating the resulting mixture in the presence of at least one recombination protein under conditions whereby recombination between the first and second recombination sites is effected, thereby introducing the heterologous nucleic acid into the artificial chromosome.
34. The method ofclaim 33, wherein the artificial chromosome is an ACes.
35. The method ofclaim 33, wherein said mixing step (a) is conducted in cells ex vivo.
36. The method ofclaim 33, wherein said mixing step (a) is conducted extracellularly in an in vitro reaction mixture.
37. The method ofclaim 33, wherein the at least one recombination protein is encoded by a bacteriophage selected from the group consisting of bacteriophage lambda, phi 80, P22, P2, 186, P4 and P1.
38. The method ofclaim 37, wherein the at least one recombination protein is encoded by bacteriophage lambda, or mutants thereof.
39. The method ofclaim 33, wherein at least one recombination protein is selected from the group consisting of Int, IHF, Xis and Cre, γδ, Tn3 resolvase, Hin, Gin, Cin and Flp.
40. The method ofclaim 32, wherein the recombination sites are selected from the group consisting of att and lox P sites.
41. The method ofclaim 33, wherein the first and/or second recombination site contains at least one mutation that removes one or more stop codons.
42. The method ofclaim 33, wherein the first and/or second recombination site contains at least one mutation that avoids hairpin formation.
43. The method ofclaim 33, wherein the first and/or second recombination site comprises at least a first nucleic acid sequence selected from the group consisting of SEQ ID NOs:41-56:
a) RKYCWGCTTTYKTRTACNAASTSGB;(SEQ ID NO:41)(m-att)b) AGCCWGCTTTYKTRTACNAACTSGB;(SEQ ID NO:42)(m-attB)c) GTTCAGCTTTCKTRTACNAACTSGB;(SEQ ID NO:43)(m-attR)d) AGCCWGCTTTCKTRTACNAAGTSGB;(SEQ ID NO:44)(m-attL)e) GTTCAGCTTTYKTRTACNAAGTSGB;(SEQ ID NO:45)(m-attP1)f) AGCCTGCTTTTTTGTACAAACTTGT;(SEQ ID NO:46)(attB1)g) AGCCTGCTTTCTTGTACAAACTTGT;(SEQ ID NO:47)(attB2)h) ACCCAGGTTTCTTGTAGAAACTTGT;(SEQ ID NO:48)(attB3)i) GTTCAGCTTTTTTGTACAAACTTGT;(SEQ ID NO:49)(attR1)j) GTTCAGCTTTCTTGTACAAACTTGT;(SEQ ID NO:50)(attR2)k) GTTCAGGTTTCTTGTACAAAGTTGG;(SEQ ID NO:51)(attR3)l) AGCCTGCTTTTTTGTACAAAGTTGG;(SEQ ID NO:52)(attL1)m) AGCCTGCTTTCTTGTACAAAGTTGG;(SEQ ID NO:53)(attL2)n) ACCCAGCTTTCTTGTACAAAGTTGG;(SEQ ID NO:54)(attL3)o) GTTCAGCTTTTTTGTACAAAGTTGG;(SEQ ID NO:55)(attP1)p) GTTCAGCTTTCTTGTACAAAGTTGG;(SEQ ID NO:56)(attP2, P3)
and a corresponding or complementary DNA or RNA sequence, wherein R=A or G, K=G or T/U, Y=C or T/U, W=A or T/U, N=A or C or G or T/U, S=C or G, and B=C or G or T/U; and
the core region does not contain a stop codon in one or more reading frames.
44. The method ofclaim 33, wherein the first and/or second recombination site comprises at least a first nucleic acid sequence selected from the group consisting of a mutated att recombination site containing at least one mutation that enhances recombinational specificity, a complementary DNA sequence thereto, and an RNA sequence corresponding thereto.
45. The method ofclaim 33, wherein the vector comprising the second site further encodes at least one selectable marker.
46. The method ofclaim 45, wherein the marker is a promoterless marker, which, upon recombination is under the control of a promoter and is thereby expressed.
47. The method ofclaim 46, wherein the first recombination site is attP and is in the sense orientation prior to recombination.
48. The method ofclaim 46, wherein the selectable marker is selected from the group consisting of an antibiotic resistance gene, and a detectable protein, wherein the detectable protein is chromogenic, fluorescent, or capable of being bound by an antibody and FACs sorted.
49. The method ofclaim 48, wherein the selectable marker is selected from the group consisting of green fluorescent protein (GFP), red fluorescent protein (RFP), blue fluorescent protein (BFP), andE. colihistidinol dehydrogenase (hisD).
50. A cell comprising, the chromosome ofclaim 1.
51. The cell ofclaim 50, wherein the cell is a nuclear donor cell.
52. The cell ofclaim 50, wherein the cell is a stem cell.
53. The stem cell ofclaim 52, wherein said stem cell is human and is selected from the group consisting of a mesenchymal stem cell, a hematopoietic stem cell, an adult stem cell and an embryonic stem cell.
54. The cell ofclaim 50, wherein the cell is mammalian.
55. The cell ofclaim 54, wherein the mammal is selected from the group consisting of humans, primates, cattle, pigs, rabbits, goats, sheep, mice, rats, guinea pigs, hamsters, cats, dogs, and horses.
56. The cell ofclaim 50, wherein the cell is a plant cell.
57. A cell comprising the platform ACes ofclaim 14.
58. The cell ofclaim 57, wherein the cell is a nuclear donor cell.
59. The cell ofclaim 57, wherein the cell is a stem cell.
60. The stem cell ofclaim 59, wherein said stem cell is human and is selected from the group consisting of a mesenchymal stem cell, a hematopoietic stem cell, an adult stem cell and an embryonic stem cell.
61. A human mesenchymal cell comprising an artificial chromosome.
62. The human mesenchymal cell ofclaim 61, wherein said artificial chromosome is an ACes.
63. The human mesenchymal cell ofclaim 62, wherein the ACes is a platform-ACes.
64. A method for introducing heterologous nucleic acid into the mesenchymal cell ofclaim 63, comprising:
(a) introducing into the cell ofclaim 63, wherein the platform-ACes has a first recombination site, a vector comprising at least a second recombination site and the heterologous nucleic acid;
(b) incubating the resulting mixture in the presence of at least one recombination protein under conditions whereby recombination between the first and second recombination sites is effected, thereby introducing the heterologous nucleic acid into the platform-ACes within the mesenchymal cell.
65. A lambda-intR mutein comprising a glutamic acid to arginine change at position 174 of wild-type lambda-intR.
66. The lambda-intR mutein ofclaim 65, wherein the lambda-intR mutein comprises SEQ ID NO:37.
67. The method ofclaim 46 wherein the promoterless marker is transcriptionally downstream of the heterologous nucleic acid, wherein the heterologous nucleic acid encodes a heterologous protein, and wherein the expression level of the selectable marker is transcriptionally linked to the expression level of the heterologous protein.
68. The method ofclaim 67, wherein the selectable marker and the heterologous nucleic acid are transcriptionally linked by the presence of a IRES between them.
69. The method ofclaim 68, wherein the selectable marker is selected from the group consisting of an antibiotic resistance gene, and a detectable protein, wherein the detectable protein is chromogenic or fluorescent.
70. The method ofclaim 69, wherein the selectable marker is selected from the group consisting of green fluorescent protein (GFP), red fluorescent protein (RFP), blue fluorescent protein (BFP), andE. colihistidinol dehydrogenase.
71. The method ofclaim 67 further comprising expressing the heterologous protein and isolating the heterologous protein.
72. A method for producing a transgenic animal, comprising introducing a platform-ACes into an embryonic cell.
73. The method ofclaim 72, wherein the embryonic cell is a stem cell.
74. The method ofclaim 72, wherein the embryonic cell is in an embryo.
75. The method ofclaim 72, wherein the platform-ACes comprises heterologous nucleic acid that encodes a therapeutic product.
76. The method ofclaim 72, wherein the transgenic animal is a fish, insect, reptile, amphibians, arachnid or mammal.
77. The method ofclaim 72, wherein the ACes is introduced by cell fusion, lipid-mediated transfection by a carrier system, microinjection, microcell fusion, electroporation, microprojectile bombardment or direct DNA transfer.
78. A transgenic animal produced by the method ofclaim 72.
79. A cell line useful for making a library of ACes, comprising a multiplicity of heterologous recombination sites randomly integrated throughout the endogenous chromosomes.
80. A method of making a library of ACes comprising random portions of a genome, comprising introducing one or more ACes into the cell line ofclaim 79, under conditions that promote the site-specific chromosomal arm exchange of the ACes into, and out of, a multiplicity of the heterologous recombination sites within the cell's chromosomal DNA; and isolating said multiplicity of ACes, thereby producing a library of ACes whereby multiple ACes have different portions of the genome within.
81. A library of cells useful for genomic screening, said library comprising a multiplicity of cells, wherein each cell comprises an ACes having a mutually exclusive portion of a chromosomal nucleic acid therein.
82. The library of cells ofclaim 81, wherein the cells of the library are from a different species than the chromosomal nucleic acid within the ACes.
83. A method of making one or more cell lines, comprising
a) integrating into endogenous chromosomal DNA of a selected cell species, a multiplicity of heterologous recombination sites,
b) introducing a multiplicity of ACes under conditions that promote the site-specific chromosomal arm exchange of the ACes into, and out of, a multiplicity of the heterologous recombination sites integrated within the cell's endogenous chromosomal DNA;
c) isolating said multiplicity of ACes, thereby producing a library of ACes whereby a multiplicity of ACes have mutually exclusive portions of the endogenous chromosomal DNA therein;
d) introducing the isolated multiplicity of ACes of step c) into a multiplicity of cells, thereby creating a library of cells;
e) selecting different cells having mutually exclusive ACes therein and clonally expanding or differentiating said different cells into clonal cell cultures, thereby creating one or more cell lines.
84. The method ofclaim 23, wherein the nucleic acid molecule with a recombination site is a PCR product.
85. Method ofclaim 23 wherein the recombinase is a protein and the recombination event occurs in vitro.
86. The method ofclaim 33, wherein the vector is a PCR product comprising a second recombination site.
87. The lambda-intR mutein ofclaim 65, wherein the mutein further comprises an amino acid signal for nuclear localization.
88. The lambda-intR mutein ofclaim 65, wherein the mutein further comprises an epitope tag for protein purification.
89. A modified iron-induced promoter comprising SEQ ID NO: 128.
90. A plasmid or expression cassette comprising the promoter ofclaim 89.
91. A vector, comprising:
a recognition site for recombination; and
a sequence of nucleotides that targets the vector to an amplifiable region of a chromosome.
92. The vector ofclaim 91, wherein the amplifiable region comprises heterochromatic nucleic acid.
93. The vector ofclaim 91, wherein the amplifiable region comprises rDNA.
94. The vector ofclaim 93, wherein the rDNA comprises an intergenic spacer.
95. The vector ofclaim 91, further comprising nucleic acid encoding a selectable marker that is not operably associated with any promoter.
96. The vector ofclaim 91, wherein the chromosome is a mammalian chromosome.
97. The vector ofclaim 91, wherein the chromosome is a plant chromosome.
98. A cell ofclaim 57 that is a plant cell, wherein the ACes platform is a MAC.
99. The plant cell ofclaim 98, wherein the MAC comprises transcriptional regulatory sequence of nucleotides derived from plants.
100. The plant cell ofclaim 99, wherein the regulatory sequence is selected from the group consisting of promoters, terminators, enhancers, silencers and transcription factor binding sites.
101. A cell ofclaim 57 that is an animal cell, wherein the ACes platform is a plant artificial chromosome (PAC).
102. The cell ofclaim 101 that is a mammalian cell.
103. The cell ofclaim 98, wherein the MAC comprises transcriptional regulatory sequence of nucleotides derived from plants.
104. The cell ofclaim 102, wherein the MAC comprises transcriptional regulatory sequence of nucleotides derived from plants.
105. The cell ofclaim 104, wherein the regulatory sequence is selected from the group consisting of promoters, terminators, enhancers, silencers and transcription factor binding sites.
106. A method, comprising:
introducing a vector ofclaim 91 into a cell;
growing the cells; and
selecting a cell comprising an artificial chromosome that comprises one or more repeat regions.
107. The method ofclaim 106, wherein sufficient portion of the vector integrates into a chromosome in the cell to result in amplification of chromosomal DNA.
108. The method ofclaim 106, wherein the artificial chromsome is an ACes.
109. A method for screening, comprising:
contacting a cell comprising a reporter ACes with test compounds or known compounds, wherein:
the reporter ACes comprises one or a plurality of reporter constructs;
a reporter construct comprises a reporter gene in operative linkage with a regulatory region responsive to test or known compounds; and
detecting any increase or decrease in signal output from the reporter, wherein a change in the signal is indicative of activity of the test or known compound on the regulatory region.
110. The method ofclaim 109, wherein the reporter is operatively linked to a promoter that controls expression of a gene in a signal transduction pathway, whereby activation or reduction in the signal indicates that the pathway is activated or down-regulated by the test compound.
111. The method ofclaim 109, wherein the reporter in the construct encodes drug resistance or encodes a fluorescent protein.
112. The method ofclaim 111, wherein the fluorescent protein is selected from the group consisting of red, green and blue fluorescent proteins.
113. The method ofclaim 109, wherein the ACes comprises a plurality of reporter-linked constructs, each with a different reporter, whereby the pathway(s) affected by the test compounds can be elucidated.
114. The method ofclaim 109, wherein a reporter is operatively linked to a promoter that is transcriptionally regulated in resopnse to DNA damage, and the test compounds are genotoxicants.
115. The method ofclaim 114, wherein the DNA damage is induced by apoptosis, necrosis or cell-cycle perturbations.
116. The method ofclaim 114, wherein unknown compounds are screened to assess whether they are genotoxicants.
117. The method ofclaim 114, wherein the promoter is a cytochrome P450-profiled promoter.
118. The method ofclaim 114, wherein the cell is in a transgenic animal and toxicity is assessed in the animal.
119. The method ofclaim 109, wherein:
the cell is a patient cell sample; the patient has a disease;
the regulatory region is one targeted by a drug or drug regimen; and
the method assesses the effectiveness of a treatment for the disease for the particular patient.
120. The method ofclaim 119, wherein the cell is a tumor cell.
121. The method ofclaim 109, wherein the cell is a stem cell or a progenitor cell, whereby expression of the reporter is operatively linked to a regulatory region exprssed in the cells to thereby identify stem cells or progenitor cell.
122. The method ofclaim 109, wherein the cell is in an animal; and the method comprises whole-body imaging to monitor expression of the reporter in the animal.
123. A reporter ACes comprises one or a plurality of reporter constructs, wherein the reporter construct comprises a reporter gene in operative linkage with a regulatory region responsive to test or known compounds.
US10/161,4032001-05-302002-05-30Chromosome-based platformsAbandonedUS20030119104A1 (en)

Priority Applications (5)

Application NumberPriority DateFiling DateTitle
US10/161,403US20030119104A1 (en)2001-05-302002-05-30Chromosome-based platforms
US11/006,076US7521240B2 (en)2001-05-302004-12-06Chromosome-based platforms
US11/082,154US20060024820A1 (en)2001-05-302005-03-15Chromosome-based platforms
US11/480,175US20060246586A1 (en)2001-05-302006-06-29Chromosome-based platforms
US12/985,478US20120064578A1 (en)2001-05-302011-01-06Chromosome-based platforms

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US29475801P2001-05-302001-05-30
US36689102P2002-03-212002-03-21
US10/161,403US20030119104A1 (en)2001-05-302002-05-30Chromosome-based platforms

Related Child Applications (3)

Application NumberTitlePriority DateFiling Date
US11/006,076DivisionUS7521240B2 (en)2001-05-302004-12-06Chromosome-based platforms
US11/082,154ContinuationUS20060024820A1 (en)2001-05-302005-03-15Chromosome-based platforms
US11/480,175ContinuationUS20060246586A1 (en)2001-05-302006-06-29Chromosome-based platforms

Publications (1)

Publication NumberPublication Date
US20030119104A1true US20030119104A1 (en)2003-06-26

Family

ID=26968714

Family Applications (5)

Application NumberTitlePriority DateFiling Date
US10/161,403AbandonedUS20030119104A1 (en)2001-05-302002-05-30Chromosome-based platforms
US11/006,076Expired - LifetimeUS7521240B2 (en)2001-05-302004-12-06Chromosome-based platforms
US11/082,154AbandonedUS20060024820A1 (en)2001-05-302005-03-15Chromosome-based platforms
US11/480,175AbandonedUS20060246586A1 (en)2001-05-302006-06-29Chromosome-based platforms
US12/985,478AbandonedUS20120064578A1 (en)2001-05-302011-01-06Chromosome-based platforms

Family Applications After (4)

Application NumberTitlePriority DateFiling Date
US11/006,076Expired - LifetimeUS7521240B2 (en)2001-05-302004-12-06Chromosome-based platforms
US11/082,154AbandonedUS20060024820A1 (en)2001-05-302005-03-15Chromosome-based platforms
US11/480,175AbandonedUS20060246586A1 (en)2001-05-302006-06-29Chromosome-based platforms
US12/985,478AbandonedUS20120064578A1 (en)2001-05-302011-01-06Chromosome-based platforms

Country Status (11)

CountryLink
US (5)US20030119104A1 (en)
EP (1)EP1390384A4 (en)
JP (2)JP4489424B2 (en)
AU (1)AU2002310275B2 (en)
BR (1)BR0209989A (en)
CA (1)CA2441937A1 (en)
HU (1)HUP0402659A3 (en)
IL (1)IL157746A0 (en)
MX (1)MXPA03010626A (en)
NZ (2)NZ528003A (en)
WO (1)WO2002097059A2 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20020160970A1 (en)*1996-04-102002-10-31Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030003435A1 (en)*2001-03-222003-01-02Chromos Molecular Systems, Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030059940A1 (en)*2001-03-222003-03-27De Jong GaryMethods for delivering nucleic acid molecules into cells and assessment thereof
US20030101480A1 (en)*1996-04-102003-05-29Gyula HadlaczkyArtificial chromosomes, uses therof and methods for preparing artificial chromosomes
US20030166282A1 (en)*2002-02-012003-09-04David BrownHigh potency siRNAS for reducing the expression of target genes
US20040033602A1 (en)*2002-06-122004-02-19Ambion, Inc.Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
US20040143861A1 (en)*1996-04-102004-07-22Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20040248094A1 (en)*2002-06-122004-12-09Ford Lance P.Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20050009028A1 (en)*2001-10-292005-01-13Nathaniel HeintzMethod for isolating cell-type specific mrnas
US20050080827A1 (en)*2003-08-182005-04-14Eaglehawk LimitedData security through dissembly of data elements or connections between elements
WO2005038020A1 (en)*2003-10-142005-04-28Biogen Idec Ma Inc.Flp-mediated recombination
US20060024820A1 (en)*2001-05-302006-02-02Edward PerkinsChromosome-based platforms
US20060143732A1 (en)*2001-05-302006-06-29Carl PerezPlant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
US20060142228A1 (en)*2004-12-232006-06-29Ambion, Inc.Methods and compositions concerning siRNA's as mediators of RNA interference
US20060174364A1 (en)*2004-03-012006-08-03Avigenics, Inc.Artificial chromosomes and transchromosomic avians
WO2006055931A3 (en)*2004-11-182006-08-10Stratatech CorpVectors for stable gene expression
US20060263882A1 (en)*2001-10-122006-11-23Keryos SpaMulti-cistronic vectors for gene transfer protocols
US20060277610A1 (en)*2002-10-292006-12-07Shunsuke IshiConstruction of knockdown animal by transferring double-stranded rna expression vector
US20070004002A1 (en)*2002-09-032007-01-04Japan Science And Technology AgencyArtificial mammalian chromosome
US20070031390A1 (en)*2005-05-182007-02-08Daniel WeeksMethods and compositions for site-specific genomic expression of nucleic acid sequences
US20070031920A1 (en)*2002-10-242007-02-08Biogen, Inc.High expression locus vector based on ferritin heavy chain gene locus
US20070271629A1 (en)*2006-05-172007-11-22Pioneer Hi-Bred International, Inc.Artificial plant minichromosomes
US20090100550A1 (en)*2006-05-172009-04-16Pioneer Hi-Bred International, Inc.Artificial Plant Minichromosomes
US20090150080A1 (en)*2005-02-162009-06-11Genetic Technologies LimitedMethods of genetic analysis involving the amplification of complementary duplicons
US20090165176A1 (en)*2006-05-172009-06-25Pioneer Hi-Bred International, Inc.Artificial Plant Minichromosomes
US20090191542A1 (en)*2006-08-232009-07-30Xcellerex, Inc.Multi-variant cell indication technique
US20090232804A1 (en)*2008-01-232009-09-17Glenmark Pharmaceuticals, S.A.,Humanized antibodies specific for von willebrand factor
US20100075423A1 (en)*2002-06-122010-03-25Life Technologies CorporationMethods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20110071049A1 (en)*2008-03-122011-03-24Nathaniel HeintzMethods and compositions for translational profiling and molecular phenotyping
US20140051843A1 (en)*2003-06-262014-02-20Life Technologies CorporationMethods and compositions for detecting promoter activity and expressing fusion proteins
US8815821B2 (en)2002-02-012014-08-26Life Technologies CorporationDouble-stranded oligonucleotides
US9777275B2 (en)2002-02-012017-10-03Life Technologies CorporationOligonucleotide compositions with enhanced efficiency
WO2025050564A1 (en)*2023-09-052025-03-13中国科学院深圳先进技术研究院Method for rapid construction of rdna array and use of method in manual regulation of rdna copy number

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2003304425A1 (en)*2002-06-042005-03-07Michele CalosMethods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
EP1711614B1 (en)2004-02-022009-01-07Pioneer Hi-Bred International, Inc.Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use
KR20070072608A (en)2004-10-222007-07-04레비비코르 인코포레이션 Ungulates with genetically modified immune system
JP4895100B2 (en)*2006-05-012012-03-14国立大学法人鳥取大学 Human artificial chromosome vector without endogenous gene
CA2656531C (en)2006-07-052012-12-11Catalyst Biosciences, Inc.Protease screening methods and proteases identified thereby
EP2348827B1 (en)2008-10-272015-07-01Revivicor, Inc.Immunocompromised ungulates
US8647841B2 (en)2008-11-282014-02-11Anton BauerArtificial chromosome vector
CA2754108A1 (en)2009-03-052010-09-10Metabolix, Inc.Propagation of transgenic plants
WO2010102293A1 (en)2009-03-062010-09-10Metabolix, Inc.Method of positive plant selection using sorbitol dehydrogenase
WO2010117785A1 (en)*2009-03-312010-10-14Temple University - Of The Commonwealth System Of Higher EducationLeptin antagonist and methods of use
BR112012005591A2 (en)2009-09-152015-09-01Metabolix Inc Generation of oilseeds producing high polyhydroxybutyrate.
RU2434944C2 (en)*2009-11-062011-11-27Учреждение Российской академии наук Центр "Биоинженерия" РАНRECOMBINANT PLASMIS DNA pZEN16 FOR TRANSFER AND EXPRESSION OF GENES IN MYCELIAL FUNGUS ACREMONIUM CHRYSOGENUM
EP2529017A2 (en)2009-12-302012-12-05Pioneer Hi-Bred International, Inc.Methods and compositions for targeted polynucleotide modification
EP3078748B1 (en)*2009-12-302021-08-11Pioneer Hi-Bred International, Inc.Methods and compositions for the introduction and regulated expression of genes in plants
AU2011238708B2 (en)*2010-03-292016-02-11The Trustees Of The University Of PennsylvaniaPharmacologically Induced Transgene Ablation system
WO2013006861A1 (en)2011-07-072013-01-10University Of Georgia Research Foundation, Inc.Sorghum grain shattering gene and uses thereof in altering seed dispersal
WO2013184768A1 (en)2012-06-052013-12-12University Of Georgia Research Foundation, Inc.Compositions and methods of gene silencing in plants
WO2014028426A1 (en)2012-08-132014-02-20University Of Georgia Research Foundation, Inc.Compositions and methods for increasing pest resistance in plants
HU230368B1 (en)2012-11-162016-03-29Magyar Tudományos Akadémia Szegedi Biológiai KutatóközpontA novel method to load a mammalian artificial chromosome with multiple genes
US20160194650A1 (en)2012-12-182016-07-07Metabolix, Inc.Transcriptional Regulation for Improved Plant Productivity
GB201414130D0 (en)*2014-08-082014-09-24Agency Science Tech & ResMutants of the bacteriophage lambda integrase
EP3247808B1 (en)*2015-01-212021-05-05Fred Hutchinson Cancer Research CenterPoint-of-care and/or portable platform for gene therapy
US11155836B2 (en)2015-02-092021-10-26CarryGenes BioengineeringCompositions and methods for monitoring in real-time construction and bioengineering of mammalian synthetic chromosomes
US11174467B2 (en)2015-04-082021-11-16Yield10 Bioscience, Inc.Plants with enhanced yield and methods of construction
CN108291208A (en)2015-11-242018-07-17葛兰素史密斯克莱知识产权发展有限公司Stable cell lines for generating retrovirus
DE102016122317A1 (en)2015-11-242017-05-24Glaxosmithkline Intellectual Property Development Limited TRANSIENT TRANSFECTION PROCEDURE FOR RETROVIRAL PRODUCTION
JP2019513397A (en)2016-04-122019-05-30シンプロイド バイオテック エルエルシーSynploid Biotek,Llc Sequential loading of multiple delivery vectors using a single selectable marker
WO2017180665A2 (en)2016-04-122017-10-19Edward PerkinsMethods for creatings synthetic chromosomes expressing biosynthetic pathways and uses thereof
EP3910058B1 (en)2016-04-122025-01-08CarryGenes Bioengineering, LLCMethods for creating synthetic chromosomes having gene regulatory systems and uses thereof
AU2017270579B2 (en)2016-05-272023-10-12The Board Of Trustees Of The University Of IllinoisTransgenic plants with increased photosynthesis efficiency and growth
WO2018112378A1 (en)2016-12-152018-06-21Synploid Biotek, LlcMethods of cell renewal
EP3583121A1 (en)*2017-02-172019-12-25Lonza LtdMulti-site specific integration cells for difficult to express proteins
WO2018169892A1 (en)*2017-03-152018-09-20Synploid Biotek, LlcCompositions and methods of chromosomal silencing
GB201706121D0 (en)*2017-04-182017-05-31Glaxosmithkline Ip Dev LtdStable cell lines for retroviral production
AU2018330033C1 (en)2017-09-052022-10-27CarryGenes BioengineeringLineage reporter synthetic chromosomes and methods of use
US20200332315A1 (en)*2017-11-022020-10-22National University Corporation Tottori UniversityMethod for high production of protein using mammalian artificial chromosome vector
JP6823791B2 (en)*2018-09-252021-02-03国立研究開発法人産業技術総合研究所 Artificial chromosome vector and transformed mammalian cell
GB201816919D0 (en)2018-10-172018-11-28Glaxosmithkline Ip Dev LtdAdeno-associated viral vector producer cell lines
WO2023275721A1 (en)*2021-06-282023-01-05Inpamac Biotech Canada Inc.Compositions, constructs, cells and methods for cell therapy
WO2023215399A1 (en)*2022-05-032023-11-09University Of Southern CaliforniaAssembling synthetic dna constructs from natural dna
WO2024075756A1 (en)*2022-10-052024-04-11株式会社LogomixCell library and method for producing same
JP7212982B1 (en)2022-10-052023-01-26株式会社Logomix Cell library and its production method
CN118546903A (en)*2023-02-242024-08-27尧唐(上海)生物科技有限公司Enzyme capable of mediating large fragment DNA integration into mammalian genome and application thereof

Citations (44)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4673640A (en)*1984-04-301987-06-16Biotechnica International, Inc.Regulated protein production using site-specific recombination
US4775630A (en)*1986-08-151988-10-04Vanderbilt UniversityTranscriptional control element adapted for regulation of gene expression in animal cells
US4801540A (en)*1986-10-171989-01-31Calgene, Inc.PG gene and its use in plants
US4920211A (en)*1988-01-041990-04-24Vanderbilt UniversityMutated adenovirus E1A gene for E1A promoter stimulation
US4959317A (en)*1985-10-071990-09-25E. I. Du Pont De Nemours And CompanySite-specific recombination of DNA in eukaryotic cells
US5190871A (en)*1989-06-121993-03-02Eli Lilly And CompanyUse of the site-specific integrating function of phage φC31
US5272071A (en)*1989-12-221993-12-21Applied Research Systems Ars Holding N.V.Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5288625A (en)*1991-09-131994-02-22Biologic Research Center Of The Hungarian Academy Of SciencesMammalian artificial chromosomes
US5396767A (en)*1992-04-061995-03-14Yamaha Hatsudoki Kabushiki KaishaEngine exhaust gas cleaning system
US5501967A (en)*1989-07-261996-03-26Mogen International, N.V./Rijksuniversiteit Te LeidenProcess for the site-directed integration of DNA into the genome of plants
US5527695A (en)*1993-01-291996-06-18Purdue Research FoundationControlled modification of eukaryotic genomes
US5658772A (en)*1989-12-221997-08-19E. I. Du Pont De Nemours And CompanySite-specific recombination of DNA in plant cells
US5691140A (en)*1995-05-181997-11-25New England Biolabs, Inc.Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions
US5695967A (en)*1995-06-071997-12-09Case Western Reserve UniversityMethod for stably cloning large repeating units of DNA
US5712134A (en)*1990-05-091998-01-27The Biological Research Center Of The Hungarian Academy Of SciencesMethod of producing a cell carrying an excess of mammalian centromeres
US5721118A (en)*1995-10-311998-02-24The Regents Of The University Of California, San DiegoMammalian artificial chromosomes and methods of using same
US5744386A (en)*1994-12-221998-04-28International Business Machines CorporationMethod of fabricating a memory cell in a substrate trench
US5804177A (en)*1993-11-151998-09-08Humphries; R. KeithMethod of using CD24 as a cell marker
US5866359A (en)*1989-01-101999-02-02Alusuisse Holdings A.G.Transactivation method of regulating foreign gene expression
US5869294A (en)*1995-06-071999-02-09Case Western Reserve UniversityMethod for stably cloning large repeating DNA sequences
US5948653A (en)*1997-03-211999-09-07Pati; SushmaSequence alterations using homologous recombination
US6025155A (en)*1996-04-102000-02-15Chromos Molecular Systems, Inc.Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6074836A (en)*1993-09-012000-06-13Boehringer Mannheim GmbhMethod of marking eukaryotic cells
US6077697A (en)*1996-04-102000-06-20Chromos Molecular Systems, Inc.Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6100092A (en)*1998-06-152000-08-08Board Of Trustees, Rutgers The State University Of New JerseyMaterials and methods for amplifying polynucleotides in plants
US6114600A (en)*1997-10-312000-09-05The United States Of America As Represented By The Secretary Of AgricultureResolution of complex integration patterns to obtain single copy transgenes
US6126320A (en)*1997-05-192000-10-03Nidec CorporationHydrodynamic pressure bearing
US6133503A (en)*1995-10-312000-10-17The Regents Of The University Of CaliforniaMammalian artificial chromosomes and methods of using same
US6143530A (en)*1995-02-232000-11-07Rhone-Poulenc Rorer S.A.Circular DNA expression cassettes for in vivo gene transfer
US6143949A (en)*1997-03-262000-11-07Japan As Represented By Director General Of Ministry Of Agriculture, Forestry And Fisheries National Institue Of Agrobiological ResourcesMethod for transferring gene
US6171861B1 (en)*1995-06-072001-01-09Life Technologies, Inc.Recombinational cloning using engineered recombination sites
US6171821B1 (en)*1998-07-242001-01-09Apoptogen, Inc.XIAP IRES and uses thereof
US6262341B1 (en)*1997-11-182001-07-17Pioneer Hi-Bred International, Inc.Method for the integration of foreign DNA into eukaryotic genomes
US6365373B2 (en)*1997-04-252002-04-02Genentech, Inc.Nucleic acids encoding NGF variants
US20020160970A1 (en)*1996-04-102002-10-31Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160410A1 (en)*1996-04-102002-10-31Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030003435A1 (en)*2001-03-222003-01-02Chromos Molecular Systems, Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030027337A1 (en)*1999-08-302003-02-06Boehringer Ingelheim Pharma KgSequence-specific DNA recombination in eukaryotic cells
US20030059940A1 (en)*2001-03-222003-03-27De Jong GaryMethods for delivering nucleic acid molecules into cells and assessment thereof
US20030113917A1 (en)*2001-03-222003-06-19Chromos Molecular Systems, Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030224522A1 (en)*2002-05-012003-12-04De Jong GaryMethods for delivering nucleic acid molecules into cells and assessment thereof
US6746870B1 (en)*1999-07-232004-06-08The Regents Of The University Of CaliforniaDNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
US20050181506A1 (en)*2001-05-302005-08-18Edward PerkinsChromosome-based platforms
US20060143732A1 (en)*2001-05-302006-06-29Carl PerezPlant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US107572A (en)*1870-09-20Improvement in shoe-fastenings
US224930A (en)*1880-02-24Harness pipe-loop attachment for wax-thread sewing-machines
US11155A (en)*1854-06-27Improvement in grass-harvesters
US109351A (en)*1870-11-15Improvement in sawing-machines
US187936A (en)*1877-02-27Improvement in detecters of counterfeit coin
US5393A (en)*1847-12-11Apparatus for clubfeet
US5270201A (en)*1988-03-241993-12-14The General Hospital CorporationArtificial chromosome vector
AU4541093A (en)*1992-06-181994-01-24Genpharm International, Inc.Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
WO1994023049A2 (en)*1993-04-021994-10-13The Johns Hopkins UniversityThe introduction and expression of large genomic sequences in transgenic animals
AUPN903196A0 (en)1996-03-291996-04-26Australian National University, TheSingle-step excision means
DE69637631D1 (en)1996-08-262008-09-18Chromo Res Inc ARTIFICIAL HERBS CHROMOSOME
AU746775B2 (en)1997-06-032002-05-02University Of Chicago, ThePlant artificial chromosome (PLAC) compositions and methods
US6331661B1 (en)1997-11-182001-12-18Pioneer Hi-Bred International, Inc.Method for directional stable transformation of eukaryotic cells
GB2331752B (en)*1997-11-282001-01-24Medical Res CouncilVectors
KR20010083061A (en)*1998-06-232001-08-31클라우디오 쿼르타Methods for Transferring the Capability to Produce a Natural Product into a Suitable Production Host
AU771111B2 (en)1998-07-212004-03-11Emd Millipore CorporationA polynucleotide comprising a ubiquitous chromatin opening element (UCOE)
AU5898599A (en)*1998-08-192000-03-14Board Of Trustees Of The Leland Stanford Junior UniversityMethods and compositions for genomic modification
TWI255853B (en)*1998-08-212006-06-01Kirin BreweryMethod for modifying chromosomes
CA2362897A1 (en)1999-03-182000-09-21The University Of ChicagoPlant centromeres
WO2000060091A2 (en)1999-04-062000-10-12Oklahoma Medical Research FoundationMethod for selecting recombinase variants with altered specificity
EP1234022B1 (en)*1999-07-232010-04-07The Regents Of The University Of CaliforniaDna recombination in eukaryotic cells by the bacteriophage phic31 recombination system
WO2001009351A1 (en)1999-08-022001-02-08Baylor College Of MedicineNovel vectors and system for selectable targeted integration of transgenes into a chromosome without antibiotic resistance markers
US7247768B1 (en)*1999-08-052007-07-24Icon Genetics, Inc.Method of making plant artificial chromosomes
JP2003512025A (en)1999-08-052003-04-02アイコン・ジェネティクス,インコーポレイテッド Method for producing plant artificial chromosomes
US7220567B2 (en)2000-05-172007-05-22Schering CorporationIsolation of Micromonospora carbonacea var africana pMLP1 integrase and use of integrating function for site-specific integration into Micromonospora halophitica and Micromonospora carbonacea chromosome
IL154063A0 (en)*2000-07-212003-07-31Us AgricultureMethods for the replacement, translocation and stacking of dna in eukaryotic genomes
KR20030051662A (en)2000-09-202003-06-25엠엘 래보러토리즈 피엘씨Polynucleotide
US6376192B1 (en)*2000-11-282002-04-23Baylor College Of MedicineMethod for screening of DNA libraries and generation of recombinant DNA constructs
EP1383541A4 (en)2001-03-222009-11-04Chromos Molecular Systems IncMethods for delivering nucleic acid molecules into cells and assessment thereof
AU2003220642C1 (en)*2002-03-292009-01-29Syngenta Participations AgLambda integrase mediated recombination in plants
BRPI0913818A2 (en)*2008-10-032017-03-28Agrisoma Biosciences Inc transgenic plant production method, transgenic plant and oil production method
US20100184128A1 (en)*2008-10-032010-07-22Dow Agrosciences LlcProduction of products of pharmaceutical interest in plant cell cultures

Patent Citations (60)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4673640A (en)*1984-04-301987-06-16Biotechnica International, Inc.Regulated protein production using site-specific recombination
US4959317A (en)*1985-10-071990-09-25E. I. Du Pont De Nemours And CompanySite-specific recombination of DNA in eukaryotic cells
US4775630A (en)*1986-08-151988-10-04Vanderbilt UniversityTranscriptional control element adapted for regulation of gene expression in animal cells
US4801540A (en)*1986-10-171989-01-31Calgene, Inc.PG gene and its use in plants
US4920211A (en)*1988-01-041990-04-24Vanderbilt UniversityMutated adenovirus E1A gene for E1A promoter stimulation
US5866359A (en)*1989-01-101999-02-02Alusuisse Holdings A.G.Transactivation method of regulating foreign gene expression
US5190871A (en)*1989-06-121993-03-02Eli Lilly And CompanyUse of the site-specific integrating function of phage φC31
US5501967A (en)*1989-07-261996-03-26Mogen International, N.V./Rijksuniversiteit Te LeidenProcess for the site-directed integration of DNA into the genome of plants
US5658772A (en)*1989-12-221997-08-19E. I. Du Pont De Nemours And CompanySite-specific recombination of DNA in plant cells
US5272071A (en)*1989-12-221993-12-21Applied Research Systems Ars Holding N.V.Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5891691A (en)*1990-05-091999-04-06The Biological Research Center Of The Hungarian Academy Of SciencesMethod of producing a cell carrying an excess of mammalian centromeres and the cell line carrying an excess of mammalian centromeres
US5712134A (en)*1990-05-091998-01-27The Biological Research Center Of The Hungarian Academy Of SciencesMethod of producing a cell carrying an excess of mammalian centromeres
US5288625A (en)*1991-09-131994-02-22Biologic Research Center Of The Hungarian Academy Of SciencesMammalian artificial chromosomes
US5396767A (en)*1992-04-061995-03-14Yamaha Hatsudoki Kabushiki KaishaEngine exhaust gas cleaning system
US5910415A (en)*1993-01-291999-06-08Purdue Research FoundationControlled modification of eukaryotic genomes
US5744336A (en)*1993-01-291998-04-28Purdue Research FoundationDNA constructs for controlled transformation of eukaryotic cells
US5527695A (en)*1993-01-291996-06-18Purdue Research FoundationControlled modification of eukaryotic genomes
US6110736A (en)*1993-01-292000-08-29Purdue Research FoundationSite-directed recombination in plants
US6074836A (en)*1993-09-012000-06-13Boehringer Mannheim GmbhMethod of marking eukaryotic cells
US5804177A (en)*1993-11-151998-09-08Humphries; R. KeithMethod of using CD24 as a cell marker
US5744386A (en)*1994-12-221998-04-28International Business Machines CorporationMethod of fabricating a memory cell in a substrate trench
US6143530A (en)*1995-02-232000-11-07Rhone-Poulenc Rorer S.A.Circular DNA expression cassettes for in vivo gene transfer
US5691140A (en)*1995-05-181997-11-25New England Biolabs, Inc.Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions
US5695967A (en)*1995-06-071997-12-09Case Western Reserve UniversityMethod for stably cloning large repeating units of DNA
US6171861B1 (en)*1995-06-072001-01-09Life Technologies, Inc.Recombinational cloning using engineered recombination sites
US5869294A (en)*1995-06-071999-02-09Case Western Reserve UniversityMethod for stably cloning large repeating DNA sequences
US5721118A (en)*1995-10-311998-02-24The Regents Of The University Of California, San DiegoMammalian artificial chromosomes and methods of using same
US6133503A (en)*1995-10-312000-10-17The Regents Of The University Of CaliforniaMammalian artificial chromosomes and methods of using same
US20030101480A1 (en)*1996-04-102003-05-29Gyula HadlaczkyArtificial chromosomes, uses therof and methods for preparing artificial chromosomes
US20020160970A1 (en)*1996-04-102002-10-31Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20040143861A1 (en)*1996-04-102004-07-22Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20040163147A1 (en)*1996-04-102004-08-19Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en)*1996-04-102000-06-20Chromos Molecular Systems, Inc.Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030083293A1 (en)*1996-04-102003-05-01Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en)*1996-04-102000-02-15Chromos Molecular Systems, Inc.Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20050153909A1 (en)*1996-04-102005-07-14Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20060095984A1 (en)*1996-04-102006-05-04Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20070061920A1 (en)*1996-04-102007-03-15Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160410A1 (en)*1996-04-102002-10-31Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6743967B2 (en)*1996-04-102004-06-01Chromos Molecular Systems Inc.Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5948653A (en)*1997-03-211999-09-07Pati; SushmaSequence alterations using homologous recombination
US6143949A (en)*1997-03-262000-11-07Japan As Represented By Director General Of Ministry Of Agriculture, Forestry And Fisheries National Institue Of Agrobiological ResourcesMethod for transferring gene
US6365373B2 (en)*1997-04-252002-04-02Genentech, Inc.Nucleic acids encoding NGF variants
US6126320A (en)*1997-05-192000-10-03Nidec CorporationHydrodynamic pressure bearing
US6114600A (en)*1997-10-312000-09-05The United States Of America As Represented By The Secretary Of AgricultureResolution of complex integration patterns to obtain single copy transgenes
US6262341B1 (en)*1997-11-182001-07-17Pioneer Hi-Bred International, Inc.Method for the integration of foreign DNA into eukaryotic genomes
US6355860B1 (en)*1998-06-152002-03-12Rutgers, The State University Of New JerseyMaterials and methods for amplifying and enhanced transcribing of polynucleotides in plants and portions thereof
US6100092A (en)*1998-06-152000-08-08Board Of Trustees, Rutgers The State University Of New JerseyMaterials and methods for amplifying polynucleotides in plants
US6171821B1 (en)*1998-07-242001-01-09Apoptogen, Inc.XIAP IRES and uses thereof
US6746870B1 (en)*1999-07-232004-06-08The Regents Of The University Of CaliforniaDNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
US20030027337A1 (en)*1999-08-302003-02-06Boehringer Ingelheim Pharma KgSequence-specific DNA recombination in eukaryotic cells
US20030186390A1 (en)*2001-03-222003-10-02De Jong GaryMethods for delivering nucleic acid molecules into cells and assessment thereof
US20030113917A1 (en)*2001-03-222003-06-19Chromos Molecular Systems, Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030059940A1 (en)*2001-03-222003-03-27De Jong GaryMethods for delivering nucleic acid molecules into cells and assessment thereof
US6936469B2 (en)*2001-03-222005-08-30Chromos Molecular Systems Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030003435A1 (en)*2001-03-222003-01-02Chromos Molecular Systems, Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US20050181506A1 (en)*2001-05-302005-08-18Edward PerkinsChromosome-based platforms
US20060024820A1 (en)*2001-05-302006-02-02Edward PerkinsChromosome-based platforms
US20060143732A1 (en)*2001-05-302006-06-29Carl PerezPlant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
US20030224522A1 (en)*2002-05-012003-12-04De Jong GaryMethods for delivering nucleic acid molecules into cells and assessment thereof

Cited By (65)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20090263898A1 (en)*1996-04-102009-10-22The Biological Research Center Of The Hungarian Academy Of SciencesArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20060150271A1 (en)*1996-04-102006-07-06Gyula HadlaczkyArtificial chromosomes, uses thereof and method for preparing artificial chromosomes
US8389802B2 (en)1996-04-102013-03-05The Biological Research Center Of The Hungarian Academy Of SciencesArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030083293A1 (en)*1996-04-102003-05-01Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030101480A1 (en)*1996-04-102003-05-29Gyula HadlaczkyArtificial chromosomes, uses therof and methods for preparing artificial chromosomes
US20020160970A1 (en)*1996-04-102002-10-31Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20040143861A1 (en)*1996-04-102004-07-22Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20040163147A1 (en)*1996-04-102004-08-19Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20060095984A1 (en)*1996-04-102006-05-04Gyula HadlaczkyArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US8288610B2 (en)1996-04-102012-10-16The Biological Research Center Of The Hungarian Academy Of SciencesArtificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030003435A1 (en)*2001-03-222003-01-02Chromos Molecular Systems, Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030059940A1 (en)*2001-03-222003-03-27De Jong GaryMethods for delivering nucleic acid molecules into cells and assessment thereof
US7294511B2 (en)2001-03-222007-11-13Chromos Molecular Systems, Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US20050112661A1 (en)*2001-03-222005-05-26Dejong GaryMethods for delivering nucleic acid molecules into cells and assessment thereof
US6936469B2 (en)*2001-03-222005-08-30Chromos Molecular Systems Inc.Methods for delivering nucleic acid molecules into cells and assessment thereof
US7521240B2 (en)2001-05-302009-04-21Smithkline Beecham CorporationChromosome-based platforms
US20060024820A1 (en)*2001-05-302006-02-02Edward PerkinsChromosome-based platforms
US20060143732A1 (en)*2001-05-302006-06-29Carl PerezPlant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
US20100221720A1 (en)*2001-05-302010-09-02Carl PerezPlant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
US20060246586A1 (en)*2001-05-302006-11-02Edward PerkinsChromosome-based platforms
US20060263882A1 (en)*2001-10-122006-11-23Keryos SpaMulti-cistronic vectors for gene transfer protocols
US8513485B2 (en)2001-10-292013-08-20Envoy Therapeutics, Inc.Non human transgenic mammal comprising a transgene comprising a nucleotide sequence encoding a ribosomal protein fused to a peptide tag
US20050009028A1 (en)*2001-10-292005-01-13Nathaniel HeintzMethod for isolating cell-type specific mrnas
US7985553B2 (en)2001-10-292011-07-26Nathaniel HeintzMethod for isolating cell type-specific mRNAs
US10106793B2 (en)2002-02-012018-10-23Life Technologies CorporationDouble-stranded oligonucleotides
US10036025B2 (en)2002-02-012018-07-31Life Technologies CorporationOligonucleotide compositions with enhanced efficiency
US9796978B1 (en)2002-02-012017-10-24Life Technologies CorporationOligonucleotide compositions with enhanced efficiency
US10626398B2 (en)2002-02-012020-04-21Life Technologies CorporationOligonucleotide compositions with enhanced efficiency
US9777275B2 (en)2002-02-012017-10-03Life Technologies CorporationOligonucleotide compositions with enhanced efficiency
US8524680B2 (en)2002-02-012013-09-03Applied Biosystems, LlcHigh potency siRNAS for reducing the expression of target genes
US9592250B2 (en)2002-02-012017-03-14Life Technologies CorporationDouble-stranded oligonucleotides
US20030166282A1 (en)*2002-02-012003-09-04David BrownHigh potency siRNAS for reducing the expression of target genes
US8815821B2 (en)2002-02-012014-08-26Life Technologies CorporationDouble-stranded oligonucleotides
US10196640B1 (en)2002-02-012019-02-05Life Technologies CorporationOligonucleotide compositions with enhanced efficiency
US20040033602A1 (en)*2002-06-122004-02-19Ambion, Inc.Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
US20100075423A1 (en)*2002-06-122010-03-25Life Technologies CorporationMethods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040248094A1 (en)*2002-06-122004-12-09Ford Lance P.Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20070004002A1 (en)*2002-09-032007-01-04Japan Science And Technology AgencyArtificial mammalian chromosome
US20070031920A1 (en)*2002-10-242007-02-08Biogen, Inc.High expression locus vector based on ferritin heavy chain gene locus
US20060277610A1 (en)*2002-10-292006-12-07Shunsuke IshiConstruction of knockdown animal by transferring double-stranded rna expression vector
US20140051843A1 (en)*2003-06-262014-02-20Life Technologies CorporationMethods and compositions for detecting promoter activity and expressing fusion proteins
US20050080827A1 (en)*2003-08-182005-04-14Eaglehawk LimitedData security through dissembly of data elements or connections between elements
EA010059B1 (en)*2003-10-142008-06-30Байоджен Айдек Ма Инк.Flp-mediated recombination
WO2005038020A1 (en)*2003-10-142005-04-28Biogen Idec Ma Inc.Flp-mediated recombination
US20070134795A1 (en)*2003-10-142007-06-14Holly PrenticeFlp-mediated recombination
US20090188002A1 (en)*2004-03-012009-07-23Avigenics, Inc.Artificial chromosomes and transchromosomic avians
US20060174364A1 (en)*2004-03-012006-08-03Avigenics, Inc.Artificial chromosomes and transchromosomic avians
WO2006055931A3 (en)*2004-11-182006-08-10Stratatech CorpVectors for stable gene expression
US20100159591A1 (en)*2004-12-232010-06-24Life Technologies CorporationMETHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE
US20060142228A1 (en)*2004-12-232006-06-29Ambion, Inc.Methods and compositions concerning siRNA's as mediators of RNA interference
US8058255B2 (en)2004-12-232011-11-15Applied Biosystems, LlcMethods and compositions concerning siRNA's as mediators of RNA interference
US8315816B2 (en)*2005-02-162012-11-20Genetic Technologies LimitedMethods of genetic analysis involving the amplification of complementary duplicons
US20090150080A1 (en)*2005-02-162009-06-11Genetic Technologies LimitedMethods of genetic analysis involving the amplification of complementary duplicons
US20070031390A1 (en)*2005-05-182007-02-08Daniel WeeksMethods and compositions for site-specific genomic expression of nucleic acid sequences
US20090165176A1 (en)*2006-05-172009-06-25Pioneer Hi-Bred International, Inc.Artificial Plant Minichromosomes
US20070271629A1 (en)*2006-05-172007-11-22Pioneer Hi-Bred International, Inc.Artificial plant minichromosomes
US20110119795A1 (en)*2006-05-172011-05-19Pioneer Hi Bred International IncArtificial plant minichromosomes
US20090100550A1 (en)*2006-05-172009-04-16Pioneer Hi-Bred International, Inc.Artificial Plant Minichromosomes
US20090191542A1 (en)*2006-08-232009-07-30Xcellerex, Inc.Multi-variant cell indication technique
US20090232804A1 (en)*2008-01-232009-09-17Glenmark Pharmaceuticals, S.A.,Humanized antibodies specific for von willebrand factor
US8236315B2 (en)2008-01-232012-08-07Glenmark Pharmaceuticals, S.A.Humanized antibodies specific for von Willebrand factor
US9816096B2 (en)2008-03-122017-11-14The Rockefeller UniversityMethods and compositions for translational profiling and molecular phenotyping
US20110071049A1 (en)*2008-03-122011-03-24Nathaniel HeintzMethods and compositions for translational profiling and molecular phenotyping
US10947546B2 (en)2008-03-122021-03-16The Rockefeller UniversityMethods and compositions for translational profiling and molecular phenotyping
WO2025050564A1 (en)*2023-09-052025-03-13中国科学院深圳先进技术研究院Method for rapid construction of rdna array and use of method in manual regulation of rdna copy number

Also Published As

Publication numberPublication date
HUP0402659A3 (en)2008-07-28
US20060024820A1 (en)2006-02-02
NZ528003A (en)2006-09-29
JP2005503778A (en)2005-02-10
US7521240B2 (en)2009-04-21
BR0209989A (en)2005-04-12
US20050181506A1 (en)2005-08-18
WO2002097059A9 (en)2003-09-25
EP1390384A2 (en)2004-02-25
HUP0402659A2 (en)2007-07-30
WO2002097059A2 (en)2002-12-05
US20060246586A1 (en)2006-11-02
WO2002097059A3 (en)2003-05-30
NZ545697A (en)2008-06-30
EP1390384A4 (en)2005-08-17
JP2009017884A (en)2009-01-29
CA2441937A1 (en)2002-12-05
JP4489424B2 (en)2010-06-23
WO2002097059B1 (en)2003-12-31
MXPA03010626A (en)2004-12-06
IL157746A0 (en)2004-03-28
US20120064578A1 (en)2012-03-15
AU2002310275B2 (en)2006-08-31

Similar Documents

PublicationPublication DateTitle
US20030119104A1 (en)Chromosome-based platforms
AU2019203955C1 (en)Multipartite signaling proteins and uses thereof
AU2022200903C1 (en)Engineered Cascade components and Cascade complexes
KR102319845B1 (en) CRISPR-CAS system for avian host cells
KR20230091894A (en) Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (PASTE)
ES2819976T5 (en) Compositions and medical uses for TCR reprogramming with fusion proteins
US20040003420A1 (en)Modified recombinase
CN113396222A (en)Adeno-associated virus (AAV) producing cell lines and related methods
KR20180043297A (en) Production of milk-oligosaccharides from microbial hosts with engineered intrinsic / extrinsic transport
JP2003534775A (en) Methods for destabilizing proteins and uses thereof
KR20230019063A (en) Triple function adeno-associated virus (AAV) vectors for the treatment of C9ORF72 associated diseases
KR20240029020A (en) CRISPR-transposon system for DNA modification
CN111094569A (en)Light-controlled viral protein, gene thereof, and viral vector containing same
KR20160002880A (en)Artificial transcription factors engineered to overcome endosomal entrapment
CN112877292A (en)Human antibody producing cell
KR20230117327A (en) An expression vector comprising a soluble alkaline phosphatase construct and a polynucleotide encoding the soluble alkaline phosphatase construct.
AU2017233862B2 (en)Methods and compositions for increased double stranded RNA production
KR20240021906A (en) Expression vectors, bacterial sequence-free vectors, and methods of making and using the same
AU2017252409A1 (en)Compositions and methods for nucleic acid expression and protein secretion in bacteroides
AU2023265204A1 (en)Virus-derived construct plasmid library and construction of same
KR20240022571A (en) Systems, methods and components for RNA-guided effector recruitment
KR20160003691A (en)Artificial transcription factors for the treatment of diseases caused by OPA1 haploinsufficiency
WO2002038613A2 (en)Modified recombinase
US20210130818A1 (en)Compositions and Methods for Enhancement of Homology-Directed Repair Mediated Precise Gene Editing by Programming DNA Repair with a Single RNA-Guided Endonuclease
US11814412B2 (en)Artificial proteins and compositions and methods thereof

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:CHROMOS MOLECULAR SYSTEMS, INC., CANADA

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PERKINS, EDWARD;PEREZ, CARL;LINDENBAUM, MICHAEL;AND OTHERS;REEL/FRAME:013196/0001;SIGNING DATES FROM 20020613 TO 20020614

ASAssignment

Owner name:PENDER NDI LIFE SCIENCES FUND (VCC) INC., CANADA

Free format text:SECURITY AGREEMENT;ASSIGNORS:CHROMOS MOLECULAR SYSTEMS, INC.;CELEXSYS, INC.;CHROMOS CORPORATION;REEL/FRAME:018454/0324

Effective date:20061018

ASAssignment

Owner name:GLAXO GROUP LIMITED, UNITED KINGDOM

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHROMOS MOLECULAR SYSTEMS, INC.;REEL/FRAME:020991/0360

Effective date:20071205

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp